Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
1.5K
Cancer Therapies02:49

Cancer Therapies

2.4K
2.4K
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness analysis of Mepitel Film for prevention of acute radiation dermatitis in breast cancer: a Canadian healthcare perspective.

Breast cancer research and treatment·2026
Same author

Development of a 3D <i>In Vitro</i> Wound Healing Model to Assess the Effect of ADSC-EVs on Vascularization.

Tissue engineering. Part A·2025
Same author

Pharmacokinetics of major indigo naturalis indole alkaloids in humans and their association with systemic aryl hydrocarbon receptor activity.

Biochemical pharmacology·2025
Same author

BCL6 is a context-dependent mediator of the glioblastoma response to irradiation therapy.

International journal of biological macromolecules·2024
Same author

Polyphenol and glucosinolate-derived AhR modulators regulate GPR15 expression on human CD4+ T cells.

The Journal of nutritional biochemistry·2023
Same author

Mepitel film for the prevention and treatment of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2023
Same journal

Erratum for the Research Article "Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer".

Science translational medicine·2026
Same journal

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Science translational medicine·2026
Same journal

Bioresponsive microneedle stent provides anastomosis and postoperative adjuvant therapy in preclinical resectable intestinal diseases.

Science translational medicine·2026
Same journal

Alzheimer's disease proteome-wide association study implicates adaptive immunity and identifies risk genes LILRB1 and SIRPA.

Science translational medicine·2026
Same journal

KSHV-infected endothelial cells expand and up-regulate angiogenic pathways and CXCR4 in patient-derived Kaposi sarcoma models.

Science translational medicine·2026
Same journal

Hypoxia-driven T cell-macrophage-stromal cross-talk sustains fibrosis in preclinical models of cutaneous chronic graft-versus-host disease.

Science translational medicine·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Ascorbate combination therapy: new tool in the anticancer toolbox?

Melanie J McConnell1, Patries M Herst

  • 1School of Biological Sciences, Victoria University of Wellington, Wellington 6012, New Zealand.

Science Translational Medicine
|February 7, 2014
PubMed
Summary
This summary is machine-generated.

High-dose ascorbate may enhance cancer treatments and reduce side effects for some patients. However, its effectiveness varies depending on the individual and the specific combination therapy used.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

9.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Related Experiment Videos

Last Updated: May 3, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

9.8K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Anticancer treatments aim to maximize efficacy while minimizing toxicity.
  • High-dose ascorbate (vitamin C) is being investigated as an adjunct therapy.
  • Patient variability influences treatment response.

Purpose of the Study:

  • To evaluate the impact of high-dose ascorbate on existing anticancer strategies.
  • To determine if ascorbate improves treatment efficacy and reduces toxicity.
  • To identify patient or therapy-specific factors influencing ascorbate's effects.

Main Methods:

  • Review of existing studies on high-dose ascorbate in cancer treatment.
  • Analysis of patient data to assess response variability.
  • Examination of different combination therapy regimens with ascorbate.

Main Results:

  • High-dose ascorbate demonstrated potential to improve anticancer treatment efficacy.
  • A reduction in treatment-related toxicity was observed in some patient cohorts.
  • The benefits of ascorbate were not universal, showing patient- and therapy-dependent outcomes.

Conclusions:

  • High-dose ascorbate shows promise as an adjuvant in cancer therapy.
  • Its clinical utility is contingent on patient-specific factors and the chosen therapeutic combinations.
  • Further research is needed to optimize ascorbate's role in oncology.